- All
- About MAA News Items
- Annual Conference News Items
- Art With Heart News Items
- Get Involved News Items
- Health Professionals News Items
- Living with MG News Items
- MG Awareness Month News Items
- Patient Tool Kit
- Policy Makers News Items
- Understanding MG News Items
Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form
Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form The Pharmaceutical Benefits Advisory Committee (PBAC) will assess the subcutaneous injection form of Vyvgart® (efgartigimod alfa) for acetylcholine receptor autoantibody positive (AChR+) gMG patients at its meeting in November 2025. Efgartigimod alfa is a…
Congenital Myasthenic Syndrome (CMS) patients – please complete this MAA survey!
The MAA would like to hear from ALL Australians diagnosed with CMS. We need to capture your numbers (parents/guardians can respond on behalf of children). We also want to learn about your experiences here in Australia regarding accessing Ruzurgi/Amifampridine/3,4-DAP as a treatment option. The supplier of Ruzurgi is working towards achieving PBS funding for CMS…
LET’S SHOW OUR APPRECIATION TO DR CARLO ANTOZZI: Don’t miss out on this incredible expert insights event
Myasthenia Alliance Australia is delighted to remind our community of an important upcoming event. 📅 Date: Monday 15 September🕛 Time: 12:30pm – 2:00pm📍 Location: Rydges South Bank, Brisbane With thanks to the generous support of Argenx, we will be welcoming Dr Carlo Antozzi to speak on “Myasthenia Gravis and Symptom Assessment Tools to Improve Outcomes.”…
Why volunteer? Experiencing the MG Patient Advocacy Organisation (PAO) Summit is just one example!
In May this year, people who are both a patient and patient advocate or representative came together in Den Haag, in The Netherlands. We came from about 15 different countries. I had not met one of them before arriving there, and yet I felt immediately at home. Although we come from different countries with different…
[Updated Link] EXPERT INSIGHTS: Myasthenia Gravis and symptom assessment tools to improve outcomes
The Myasthenia Alliance Australia are delighted to announce an in-person event to be hosted in Brisbane on Monday September 15th from 12 midday. We thank Argenx for supporting this opportunity to hear from Dr Carlo Antozzi speaking on “Myasthenia Gravis and symptom assessment tools to improve outcomes”. This is a significant educational opportunity for patients…
You are not alone in your experiences!
The MAA captured some invaluable information about our community as a part of the webinar hosted in January 2025. The webinar heard from leading Specialists who explained the new treatments which are currently seeking PBS funding. This webinar can be viewed here. The information collected was incorporated into the MAA Submission to the PBAC. The…
Conversations continue for access to new treatments
We appreciate that it has been a couple of months since the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that 4 new treatments for AChR+ generalised MG patients be listed on the Pharmaceutical Benefits Scheme (PBS)… In this time, the MAA has continued conversations with clinicians, government, and industry stakeholders to make sure we understand the progress…
A Decade of Progress and a Clear Vision for the Future
As the Myasthenia Alliance Australia (MAA) marks over ten years of advocacy, research, and awareness, our latest Achievements Poster offers a powerful snapshot of what a committed patient-led movement can accomplish. From grassroots fundraising to national policy impact, MAA’s journey is one of collaboration, determination, and progress. Since its inception in 2014 as a partnership…
OH MG with Chloe Wigg
Myasthenia Gravis Awareness Month went to a new level this year with the Oh MG Art Exhibition held at the Logan Art Gallery in Brisbane. The artist, Chloe Wigg, who also has MG, worked for several years to stage this wonderful exhibition which highlights MG as a snowflake condition. The use of Mestinon bottles also…
MGBase launch paper has been published and is online!
MGBase Launch Paper Now Published The MGBase registry launch paper is a landmark initiative bringing together deidentified clinical data from over 1,200 MG patients across 15 countries. Built on the proven MSBase platform, this collaborative research tool enables long-term insights into treatment outcomes, disease progression, and global variations in care. Backed by Myasthenia Alliance Australia,…